Holen Sie sich die Stockscreener-App
71.05
0.69%
0.49
Vorhandelsmarkt:
70.01
-1.04
-1.46%
Schlusskurs vom Vortag:
$70.56
Offen:
$70.66
24-Stunden-Volumen:
2.14M
Relative Volume:
1.08
Marktkapitalisierung:
$13.69B
Einnahmen:
$4.08B
Nettoeinkommen (Verlust:
$32.48M
KGV:
37.59
EPS:
1.89
Netto-Cashflow:
$16.80M
1W Leistung:
-11.72%
1M Leistung:
+7.02%
6M Leistung:
+24.24%
1J Leistung:
+29.87%
1-Tages-Spanne:
$70.25
$71.68
1-Wochen-Bereich:
$65.02
$80.46
52-Wochen-Spanne:
$50.35
$83.95
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Vergleichen Sie INCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| INCY | 71.05 | 13.69B | 4.08B | 32.48M | 16.80M | 1.89 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Connor Clark & Lunn Investment Management Ltd. Lowers Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
What Are Wall Street Analysts' Target Price For Incyte Stock? - Barchart
What Are Wall Street Analysts' Target Price for Incyte Stock? - Inkl
Merck (MRK) Eyes Incyte (INCY) for Possible Acquisition - Value the Markets
Incyte Sinks On Setback For 2 Drugs Acquired In $750M Buyout: Retail Chatter Hits One-Year High - MSN
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
U.S. Indexes Ended Tuesday Mixed As Super Micro Computer Led, Incyte Lagged - Barron's
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges - AOL
Incyte stock maintains Outperform rating despite study pause - Investing.com
Incyte (NASDAQ:INCY) Shares Gap DownHere's Why - MarketBeat
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study - Yahoo Finance
Merck ‘linked’ to takeover bid for Incyte, Sky News says - TipRanks
Incyte seesaws on report of potential Merck takeover interest (NASDAQ:INCY) - Seeking Alpha
What's Going On With Incyte Shares Tuesday? - Benzinga
Incyte Is the S&P 500’s Worst Performer Today. What’s Hitting the Stock. - MSN
Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study - Investopedia
Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Incyte Stock Is S&P 500’s Worst Performer. Here’s Why. - Barron's
Incyte Faces Challenges but Remains Focused on Strategic Growth - Yahoo Finance
Incyte sinks on setback for drugs acquired in $750M buyout - BioPharma Dive
Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. - Yahoo! Voices
Incyte (NASDAQ:INCY) Given Neutral Rating at Cantor Fitzgerald - MarketBeat
Incyte price target lowered to $86 from $90 at BofA - TipRanks
RBC maintains sector perform on Incyte shares, cuts target following '262 pause - Investing.com
One Paused, One Dropped: Incyte’s Skin Drug Acquisitions Hit Problems - Citeline News & Insights
Incyte’s $750M Escient Bet Flops as Skin Disease Assets Stumble - BioSpace
Incyte culls one Escient-acquired dermatology programme, pauses another - FirstWord Pharma
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
After-hours movers: Super Micro Computer, Bakkt Holdings, Incyte, and more - Investing.com
Incyte to pause MRGPRX2 program in CSU, suspend MRGPRX4 in CP - TipRanks
Incyte (INCY) will pause enrollment in ongoing Phase 2 study of MRGPRX2 in chronic spontaneous urticaria - StreetInsider.com
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs - Yahoo Finance
Dr. Pimple Popper gets personal with eczema in Incyte’s Moments of Clarity push - MM+M Online
Seizert Capital Partners LLC Has $6.24 Million Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Cuts Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects - Insider Monkey
Incyte Co. (NASDAQ:INCY) Shares Purchased by Mizuho Securities USA LLC - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Principal Financial Group Inc. - MarketBeat
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte price target raised to $80 from $72 at RBC Capital - TipRanks
KBC Group NV Sells 563,357 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte's SWOT analysis: stock faces patent cliff as pipeline progresses By Investing.com - Investing.com Australia
Incyte to Present at Citi's 2024 Global Healthcare Conference in Miami | INCY Stock News - StockTitan
INCY (Incyte) Cash Flow from Operations : $102 Mil (TTM As of Sep. 2024) - GuruFocus.com
Incyte's SWOT analysis: stock faces patent cliff as pipeline progresses - Investing.com
Anal Cancer Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp & Dohme, Dustin Deming, Advaxis - The Globe and Mail
Anal Cancer Market Revenue to Expand Significantly by 2034, - openPR
Incyte Co. (NASDAQ:INCY) Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Amalgamated Bank - MarketBeat
Los Angeles Capital Management LLC Lowers Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.90%
1.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):